Phase I Trial of Periocular Topotecan in Retinoblastoma

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a dose-escalation study aimed to assess the toxicity (and marginally the activity) of periocular topotecan in patients with relapsed-resistant retinoblastoma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital JP Garrahan
• Treatments: Topotecan

Criteria

Inclusion Criteria:

• Group Vb (Reese Ellsworth)

• Relapsed or progressed after carboplatin-based regimens and external beam radiotherapy

• Enucleation of the contralateral eye

• Normal renal and liver function

Exclusion Criteria:

• Presence of glaucoma, rubeosis iridis, anterior chamber extension

• Extraocular disease

• Adequate follow up impossible for social reasons